Who are Excedrin Extra Strength Pain Reliever's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cytotec, MESALAMINE, Zomiperac, Pepto-Bismol, Bromfenac Sodium 0.07%, Pranoprofen Eyedrops.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nsaid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Excedrin Extra Strength Pain Reliever — Competitive Intelligence Brief

Excedrin Extra Strength Pain Reliever (NSAID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal Anti-inflammatory Drug [EPC]. Area: Immunology.

marketed Nonsteroidal Anti-inflammatory Drug [EPC] Cyclooxygenase Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Excedrin Extra Strength Pain Reliever (NSAID) — Haleon Us Holdings.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Excedrin Extra Strength Pain Reliever TARGET	NSAID	Haleon Us Holdings	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Cyclooxygenase	2004-01-01
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
MESALAMINE	MESALAMINE		marketed	Aminosalicylate [EPC]	Cyclooxygenase	1987-01-01
Zomiperac	ZOMEPIRAC		marketed	zomepirac	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase	1980-01-01
Pepto-Bismol	bismuth subsalicylate	Generic (Procter & Gamble)	marketed	Bismuth [EPC]	Cyclooxygenase	1939-01-01
Bromfenac Sodium 0.07%	Bromfenac Sodium 0.07%	Retina Research Institute, LLC	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Pranoprofen Eyedrops	Pranoprofen Eyedrops	Università degli Studi di Brescia	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1, COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-07-24 — MESALAMINE · 7645801 · Compound · US
2028-06-06 — MESALAMINE · 8217083 · Formulation · US
2028-06-06 — MESALAMINE · 8436051 · Formulation · US
2030-05-01 — MESALAMINE · 8865688 · Method of Use · US

Sponsor landscape (Nonsteroidal Anti-inflammatory Drug [EPC] class)

· 8 drugs in this class
Pfizer · 2 drugs in this class
Assiut University · 1 drug in this class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
Centro Hospitalar Lisboa Ocidental · 1 drug in this class
Dartmouth-Hitchcock Medical Center · 1 drug in this class
Dr. Vishwanath Karad MIT World Peace University · 1 drug in this class
Dr. Reddy's Laboratories Limited · 1 drug in this class
Generic (originally Boots Group) · 1 drug in this class
Boehringer Ingelheim · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Excedrin Extra Strength Pain Reliever — Competitive Intelligence Brief. https://druglandscape.com/ci/nsaid. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab